Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Buy" from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $8.20.

A number of analysts have commented on the stock. HC Wainwright restated a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Monday, May 19th. Chardan Capital reissued a "buy" rating and issued a $6.00 price target on shares of Gain Therapeutics in a research note on Friday, March 28th. Finally, Scotiabank started coverage on Gain Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $12.00 price target on the stock.

Gain Therapeutics Trading Up 4.7%

NASDAQ GANX traded up $0.08 during mid-day trading on Friday, hitting $1.79. The company's stock had a trading volume of 356,601 shares, compared to its average volume of 296,940. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $3.19. The stock's fifty day simple moving average is $1.86 and its two-hundred day simple moving average is $1.99. The firm has a market capitalization of $53.61 million, a P/E ratio of -2.08 and a beta of 0.11.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). Research analysts expect that Gain Therapeutics will post -1 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GANX. Sprott Inc. bought a new stake in Gain Therapeutics in the fourth quarter valued at $30,000. Bridgeway Capital Management LLC bought a new stake in shares of Gain Therapeutics during the fourth quarter worth $65,000. Kovitz Investment Group Partners LLC bought a new stake in shares of Gain Therapeutics during the first quarter worth $91,000. Northern Trust Corp boosted its holdings in Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after acquiring an additional 39,642 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Gain Therapeutics in the fourth quarter valued at about $198,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.